Article info

Original research
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies

Authors

  1. Correspondence to Dr Dominique Velin, Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, 1011 Lausanne, Switzerland; dominique.velin{at}chuv.ch
View Full Text

Citation

Oster P, Vaillant L, Riva E, et al
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies

Publication history

  • Received October 17, 2020
  • Accepted June 24, 2021
  • First published July 12, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.